On Open-Label Study in Participants With Systemic Lupus Erythematosus

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease

In brief

The purpose of this SLE study is to evaluate the long-term safety and efficacy of LY2127399 in eligible SLE participants who have completed the core studies (NCT01196091) (NCT01205438).

Key facts

Study ID

NCT01488708

Run by

Eli Lilly and Company

People needed

1518

Starts

2012-01-01

Expected to finish

2015-10-01

Last updated by the study team

2018-05-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have completed 52 weeks of treatment in core studies (NCT01196091) (NCT01205438)
• Given written informed consent
• Test negative for pregnancy at the time of enrollment
• Agree to use a reliable method of birth control

You may not qualify if…

• Unwilling to comply with study procedures
• Any condition that renders the participants unable to understand the nature and scope and possible consequences of the study
• Any condition that in the opinion of the investigator poses an unacceptable risk to the participants if study drug would be administered

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician — Irving, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.